1.	A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1 Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CDX1401-01, NCT00948961
2.	Randomized, Double Blind, Placebo-controlled Topical Resiquimod Adjuvant for NY-ESO-1 Protein Vaccination Phase: Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: NYU 05-409, NCT00821652
3.	Vaccine Therapy and Resiquimod in Treating Patients With Stage II, Stage III, or Stage IV Melanoma That Has Been Completely Removed by Surgery Phase: No phase specified Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: MC0578, P30CA015083, 169-06, MAYO-MC0578, NCT00470379